Stockreport

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations
PDF ARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range15N-ureagenesis data provide first evidence of an mRNA therapeutic impro [Read more]